Levoleucovorin

Generic Name
Levoleucovorin
Brand Names
Fusilev, Khapzory
Drug Type
Small Molecule
Chemical Formula
C20H23N7O7
CAS Number
68538-85-2
Unique Ingredient Identifier
990S25980Y
Background

Levoleucovorin is the enantiomerically active form of Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin). Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro, the levo-isomer has been shown...

Indication

Levoleucovorin is indicated for use as rescue therapy following high-dose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists. Levoleucovorin, as the product Fusilev (FDA, dosed at one-half the usual dose of racemic d,l-leucovorin), has an additional indication for use...

Associated Conditions
Advanced Colorectal Cancer, Folic acid antagonist overdose, Metastatic Colorectal Cancer (CRC)
Associated Therapies
Rescue after high-dose methotrexate therapy in osteosarcoma therapy
Clinical Trials
Related News

Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer

First Posted Date
2024-07-19
Last Posted Date
2024-07-19
Lead Sponsor
National Cancer Institute, Naples
Target Recruit Count
500
Registration Number
NCT06509126
Locations
🇮🇹

Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli, Italy

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

First Posted Date
2024-06-24
Last Posted Date
2024-12-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
130
Registration Number
NCT06469944
Locations
🇺🇸

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927), Tucson, Arizona, United States

🇧🇷

Liga Norte Riograndense Contra o Câncer ( Site 6303), Natal, Rio Grande Do Norte, Brazil

🇩🇪

Facharztzentrum Eppendorf-Facharztzentrum Eppendorf ( Site 6807), Hamburg, Germany

and more 16 locations

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

First Posted Date
2023-07-14
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
66
Registration Number
NCT05945823
Locations
🇺🇸

University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California, United States

🇺🇸

Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States

🇺🇸

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

and more 19 locations

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

First Posted Date
2022-02-24
Last Posted Date
2024-11-13
Lead Sponsor
Seagen Inc.
Target Recruit Count
400
Registration Number
NCT05253651
Locations
🇺🇸

Palo Verde Cancer Specialists, Glendale, Arizona, United States

🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

🇺🇸

Pacific Cancer Medical Center, Anaheim, California, United States

and more 229 locations

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

First Posted Date
2021-07-02
Last Posted Date
2024-12-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
862
Registration Number
NCT04949256
Locations
🇨🇷

PROCLINICAL Pharma ( Site 0904), San José, San Jose, Costa Rica

🇨🇳

Shanxi Provincial Cancer Hospital ( Site 8019), Taiyuan, Shanxi, China

🇨🇳

West China Hospital of Sichuan University ( Site 8048), Chengdu, Sichuan, China

and more 192 locations

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

First Posted Date
2019-12-24
Last Posted Date
2024-11-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
703
Registration Number
NCT04210115
Locations
🇺🇸

Greater Baltimore Medical Center ( Site 0031), Baltimore, Maryland, United States

🇺🇸

Allegheny Health Network ( Site 0042), Pittsburgh, Pennsylvania, United States

🇧🇷

ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088), Ijui, Rio Grande Do Sul, Brazil

and more 167 locations

Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab

First Posted Date
2018-10-09
Last Posted Date
2024-01-31
Lead Sponsor
Asan Medical Center
Target Recruit Count
20
Registration Number
NCT03698461
Locations
🇰🇷

Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers

First Posted Date
2017-09-27
Last Posted Date
2022-04-25
Lead Sponsor
Institut Cancerologie de l'Ouest
Target Recruit Count
34
Registration Number
NCT03294252
Locations
🇫🇷

ICO René Gauducheau, Saint-Herblain, France

🇫🇷

Hopital Begin, Saint-Mandé, France

🇫🇷

Centre Hospitalier Lyon Sud, Pierre-Bénite, France

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

First Posted Date
2017-07-19
Last Posted Date
2018-03-27
Lead Sponsor
Fujian Cancer Hospital
Registration Number
NCT03222089
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

First Posted Date
2013-08-20
Last Posted Date
2020-01-28
Lead Sponsor
The Christie NHS Foundation Trust
Target Recruit Count
162
Registration Number
NCT01926236
Locations
🇬🇧

North Cumbria University Hospitals, Carlisle, United Kingdom

🇬🇧

Maidstone Hospital, Maidstone, United Kingdom

🇬🇧

The Christie NHS Foundation Trust, Manchester, United Kingdom

and more 14 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy